Table 4.
Summary of single institution retrospective series evaluating SBRT as a bridge to transplant for HCC
| Study | No. patients, No. lesions | RT dose | Median tumor size | pCR rate | cCR rate | Dropout rate | Toxicity |
|---|---|---|---|---|---|---|---|
| Facciuto et al8 | 17, 22 | 24-36 Gy in 2-4 fx | 2.01 cm | 14% | 30% | NR | 2 patients with post-SBRT nausea, 1 patient with acute liver decompensation |
| O’Connor et al9 | 10, 11 | 33-54 Gy in 3 fx | 3.4 cm | 27% | NR | 0% | 40% with acute grade 1-2 toxicity, no ≥grade 3 toxicity |
| Gresswell et al10 | 12, 17 | 30-50 Gy in 4-6 fx | 2.3 cm | 46% | 80% | 8% | No ≥grade 3 acute toxicity |
| Moore et al11 | 23, NR | 30-54 Gx in 3-5 fx | 2.5 cm | 27.3 % | NR | 30% | 1 patient (CP B8) developed RILD |
| Uemura et al12 | 22, 25 | 40-50 Gy in 4-6 fx | 3.2 cm | 28% | NR | 9% | No ≥grade 3 toxicity |
| Jacob et al13 | 12, 18 | 27-45 Gy in 2-6 fx | 4.2 cm | 100% | NR | 42% | No ≥grade 3 toxicity |
| Garg et al (current study) | 20, 26 | 30-63 Gy in 3-6 fx | 3.05 cm | 62% | 76% | 22% | No ≥grade 3 toxicity |
Abbreviations: cCR = clinical complete response; CP = Child-Pugh; HCC = hepatocellular carcinoma; NR = not reported; pCR = pathologic complete response; RILD = radiation-induced liver disease; RT = radiation therapy; SBRT = stereotactic body radiation therapy.